DENTSPLY SIRONA Inc. (XRAY) Stock Price & Analysis
DENTSPLY SIRONA Inc. (XRAY) closed at USD 9.5 on Thursday, October 22, 2026, up 4.63% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 9.08; the Oct 22, 2026 session ranged USD 9.1–9.55 on volume of 4,892,197 shares. Market capitalization is $1.89B, with a 52-week range of USD 8.32–14.76 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/XRAY.md
Key facts (XRAY)
- Last four reported quarters (through Jun 30, 2026): revenue $3.64B, net income -$546M (-15.0% margin), free cash flow $143M (SEC filings).
- 3 of 80 tracked superinvestors hold XRAY (13F, Q2 2026): 0 new, 2 added, 1 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 5 Form 4 filings, $516K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 2.76 on a 1–5 scale) (17 analysts), mean target USD 12.53 (range 9–17).
- Total return with dividends: 1Y -26.8% vs S&P 500 +14.9%; 5Y -81.9% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.31, revenue estimate $862M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (XRAY)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $4.23B | $3.92B | $3.96B | $3.79B | $3.68B | $3.64B |
| Gross profit | $2.35B | $2.13B | $2.09B | $1.96B | $1.84B | — |
| Operating income | $608M | -$937M | -$85.0M | -$879M | -$422M | -$310M |
| Net income | $411M | -$950M | -$132M | -$910M | -$598M | -$546M |
| EPS (diluted) | $1.87 | -$4.41 | -$0.62 | -$4.48 | -$3.00 | — |
| Free cash flow | $515M | $368M | $228M | $281M | $104M | $143M |
| Gross margin | 55.5% | 54.2% | 52.6% | 51.6% | 50.0% | — |
| Operating margin | 14.4% | -23.9% | -2.1% | -23.2% | -11.5% | -8.5% |
| Net margin | 9.7% | -24.2% | -3.3% | -24.0% | -16.3% | -15.0% |
| Revenue growth | +26.7% | -7.3% | +1.1% | -4.3% | -3.0% | — |
| Cash + short-term investments | $339M | $365M | $334M | $272M | $326M | — |
| Total debt | $1.92B | $1.87B | $1.91B | $1.75B | $2.28B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (XRAY)
P/S 0.5x · EV/EBITDA 99.5x · EV/Sales 1.1x · P/FCF 13.2x · P/B 1.4x · FCF yield 7.55% · Earnings yield -28.83% · Dividend yield (paid, TTM) 5.07% · Net debt $1.99B · EV $3.88B
Superinvestors (SEC 13F-HR, Q2 2026) (XRAY)
3 of 80 tracked investors hold XRAY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Alex Roepers | Atlantic Investment Management | 12.18% | $23.4M | Added +261.1% |
| John Rogers | Ariel Investments | 0.85% | $85.2M | Added +25.7% |
| First Eagle Investment | First Eagle Investment Management | 0.02% | $9.0M | Reduced -94.4% |
Insider purchases (SEC Form 4, open-market, last ~7 months) (XRAY)
5 purchases, $516K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-15 | Hosein Clyde | Director | 6,500 | $65K | 9.98 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-15 | Gladden Brian T | Director | 9,985 | $100K | 10.02 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-12 | McKeon Brian P | Director | 10,000 | $101K | 10.12 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-11 | Holden Betsy D | Director | 10,086 | $100K | 9.88 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-11 | Barber Michael J | Director | 15,175 | $150K | 9.88 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (XRAY)
Consensus Hold (mean 2.76 on a 1–5 scale), 17 analysts; mean target USD 12.53 (low 9, high 17).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Mizuho | Target lowered | Neutral | $14 → $12 |
| 2026-10-14 | Leerink Partners | Target lowered | Market Perform | $14 → $10 |
| 2026-10-09 | Piper Sandler | Target lowered | Neutral | $14 → $12 |
| 2026-09-17 | BMO Capital | Target lowered | Market Perform | $13 → $10 |
| 2026-08-24 | Barclays | Target raised | Underweight | $9 → $11 |
| 2026-07-29 | Piper Sandler | Target raised | Neutral | $13 → $14 |
| 2026-07-09 | BMO Capital | Initiated | Market Perform | $12 |
Total return (dividends reinvested) (XRAY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -26.8% | -81.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -26.9% | -28.9% |
| Volatility (annualized) | 47.9% | 38.5% |
| Max drawdown | -42.6% (Feb 2026→Oct 2026) | -83.8% (Feb 2022→Oct 2026) |
XRAY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.31 | $0.37 | -16.7% | $862.4M | 16 |
| Next quarter (ends Dec 2026) | $0.46 | $0.43 | +5.5% | $935.1M | 16 |
| Current fiscal year (ends Dec 2026) | $1.49 | $1.42 | +5.2% | $3.57B | 17 |
| Next fiscal year (ends Dec 2027) | $1.49 | $1.55 | -3.8% | $3.61B | 17 |
XRAY options: expected move
Options price a move of about ±13.7% (±$1.30) by Nov 20, 2026, which includes earnings on Nov 5, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 56.6% | ±13.7% |
| Jan 15, 2027 | 84 | 46.7% | ±18.8% |
| Apr 16, 2027 | 175 | 49.5% | ±28.0% |
30-day implied volatility 50.7% vs 47.8% realized over the last 30 trading days. Put/call ratio (volume) 0.1. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 9.5 |
|---|---|
| Change | ▲ 4.63% (up) |
| Previous Close | USD 9.08 |
| Open | USD 9.13 |
| Day Range | USD 9.1 – 9.55 |
| 52-Week Range | USD 8.32 – 14.76 |
| Volume | 4,892,197 shares |
| Market Cap | $1.89B |
| Exchange | NMS |
Technical Analysis (XRAY)
Nexqual's technical model rates XRAY "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 52 (neutral) |
| vs SMA50 | Below (USD 9.91) |
| MACD | -0.28 (negative) |
Analyst Ratings (XRAY)
Wall Street analysts rate XRAY "Hold" based on 17 analysts, with a mean price target of USD 12.53 (range USD 9–17), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 12.53 |
| High Target | USD 17 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 4 / 12 / 1 |
Earnings (XRAY)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.31 |
| Revenue Estimate | $862.41M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.52 vs est 0.35 ▲ beat |
| 2026-03-31 | USD 0.27 vs est 0.27 ▼ miss |
| 2025-12-31 | USD 0.27 vs est 0.29 ▼ miss |
| 2025-09-30 | USD 0.37 vs est 0.45 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (XRAY)
| Total Revenue | $3.64B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -4.10% |
| Gross Margin | +49.52% |
| Operating Margin | +9.24% |
| Profit Margin | -14.99% |
| ROE | -33.03% |
| Debt / Equity | 1.72 |
| Current Ratio | 1.63 |
| Total Cash | $239.00M |
| Total Debt | $2.33B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $143.00M (3.9% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (XRAY)
Nexqual rates DENTSPLY SIRONA Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 50%, operating 9% (last 12 months) |
| Balance Sheet | Weak — $239M cash and investments vs $2.22B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $143M (last 4 quarters to Jun 2026, SEC), slim 3.9% margin |
| Efficiency | Critical — ROE -33%, ROA 2.0% |
Ownership (XRAY)
| Insider Ownership | +0.65% |
|---|---|
| Institutional Ownership | +116.66% |
| Shares Outstanding | 199.35M |
| Float | 187.87M |
| Short % of Float | +14.29% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LMAT | LeMaitre Vascular, Inc. | USD 85.33 | ▲ 1.98% |
| KMTS | Kestra Medical Technologies, Lt | USD 28.32 | ▲ 3.7% |
| ATRC | AtriCure, Inc. | USD 59.3 | ▲ 2.83% |
| WRBY | Warby Parker Inc. | USD 25.67 | ▲ 0.16% |
| PLSE | Pulse Biosciences, Inc | USD 52.68 | ▲ 2.67% |
| NVST | Envista Holdings Corporation | USD 23.97 | ▲ 3.36% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt